All In Biotech

Drug Trial Radar · NCT07150988

A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Sep 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Sep 26, 2025

Primary completion

Nov 6, 2026

Study completion Nov 6, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.

Conditions

  • Psoriasis

Interventions

  • HSK44459 dose level 1Drug

    HSK44459 dose level 1 oral administration

  • HSK44459 dose level 2Drug

    HSK44459 dose level 2 orally administration

  • placeboDrug

    placebo oral adminisitration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects who have ≥75% reduction in PASI (PASI-75).Time frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.